Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5967157 | 0.91 | HRH1 (0.59) | OPRK1KMT2AMEN1NPSR1HRH1 | |
| SCHEMBL17444420 | 0.87 | SIRT2 (0.58) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL17444419 | 0.87 | SIRT2 (0.58) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL14069202 | 0.82 | CTRB1 (0.60) | OPRK1ALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL7398976 | 0.82 | CTRB1 (0.60) | OPRK1ALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL7398974 | 0.82 | CTRB1 (0.60) | OPRK1ALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL17444427 | 0.82 | ITGB3 (0.58) | KYNUALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL17444429 | 0.82 | ITGB3 (0.58) | KYNUALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL27122575 | 0.81 | ITGB3 (0.55) | ALDH1A1KMT2AMEN1NPSR1HRH1 | |
| SCHEMBL27273354 | 0.81 | SIRT2 (0.54) | ALDH1A1KMT2AMEN1NPSR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203337-A1 | USE OF 2-AMINO-THIAZOLINE DERIVATIVES AS INHIBITORS OF INDUCIBLE NO-SYNTHASE | AVENTIS PHARMA S.A. (FR) | 2007-08-30 | — | — | US | claimed |
| EP-1446393-B1 | 2-AMINO-THIAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF INDUCIBLE NO-SYNTHASE | AVENTIS PHARMA SA (FR) | 2006-03-08 | — | — | EP | claimed |
| US-20050288501-A1 | Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2005-12-29 | — | — | US | claimed |
| EP-1446393-A1 | 2-AMINO-THIAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF INDUCIBLE NO-SYNTHASE | Aventis Pharma S.A. (FR) | 2004-08-18 | — | — | EP | claimed |
| WO-2003040115-A1 | 2-AMINO-THIAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF INDUCIBLE NO-SYNTHASE | AVENTIS PHARMA S.A. (FR) | 2003-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203337-A1 | USE OF 2-AMINO-THIAZOLINE DERIVATIVES AS INHIBITORS OF INDUCIBLE NO-SYNTHASE | NOS2, PAH, TH | KYNU 784/4885OPRK1 3314/4885ALDH1A1 1923/4885 |
| US-20050288501-A1 | Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase | NOS2, TH, PAH | KYNU 685/4885OPRK1 3082/4885ALDH1A1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.